OTC Markets Group Inc. (OTCM)
OTCMKTS · Delayed Price · Currency is USD
55.72
-0.26 (-0.46%)
Apr 24, 2026, 11:48 AM EST
← View all transcripts

Earnings Call: Q1 2022

May 12, 2022

Operator

Ladies and gentlemen, thank you for standing by, and welcome to the OTC Markets Group first quarter 2022 earnings conference call. At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star one on your telephone. Please be advised that today's conference is being recorded. If you require any further assistance, please press star, then zero. I would now like to hand the conference over to your speaker, Mr. Dan Zinn, General Counsel. Please go ahead.

Dan Zinn
General Counsel and Chief of Staff, OTC Markets Group

Thank you, operator. Good morning, and welcome to the OTC Markets Group first quarter 2022 earnings conference call. With me today are Cromwell Coulson, our President and Chief Executive Officer, and Antonia Georgieva, our Chief Financial Officer. Today's call will be accompanied by a slide presentation. Our earnings press release and the presentation are each available on our website. Certain statements during this call and in our presentation may relate to future events or expectations and, as such, may constitute forward-looking statements. Actual results may differ materially from these forward-looking statements. Information concerning risks and uncertainties that may impact our actual results is contained in the Risk Factors section of our 2021 annual report, which is also available on our website. For more information, please refer to the safe harbor statement on slide three of the earnings presentation.

With that, I'd like to turn the call over to Cromwell Coulson.

Cromwell Coulson
President and CEO, OTC Markets Group

Thank you, Dan. Good morning, everyone. Thank you for joining us today. The tragic war in Ukraine and the ongoing effects of the COVID pandemic continue to influence communities and economies across the globe. The resulting volatility impacts the broker-dealers, companies, and investors that rely on our markets and our data. One point remains clear. We must continue to adapt in a changing business environment. It is crucial, especially in uncertain times, that we focus on areas where we have control of the inputs to be agents of positive change and deliver consistent improvement that creates ongoing value for our clients. Our team's dedication, collaboration, and execution across all levels remains extraordinary. I am honored to work with this talented group. We all share a commitment to serving our clients, ensuring that our mission-critical markets operate smoothly today, and building our services for a better tomorrow.

Against this backdrop, our business delivered solid results during the first quarter. Our year-over-year growth slowed following record results in unprecedented trading volumes during the first quarter of 2021. We saw lower transaction-based revenues consistent with industry-wide trends, while user demand for our corporate services and market data business lines continued their upward trajectory. This shifted the overall balance of our business lines with corporate services growth and market data subscription revenues taking up the slack for lower transaction fees. Gross revenues remained roughly flat year-over-year, while revenues less transaction-based expenses, net income, operating profit margin, and earnings per share all experienced growth. Antonia will cover our financial results in more detail in a few moments. We remain big believers in including transaction-based fees in our revenue mix.

Clients benefit from the variability of costs tracking their trading volumes, and we share upside opportunities in strong trading environments. With last quarter's normalized volumes, our OTC Link team has continued to grind away, growing subscribers across ATSs and gaining market share on our ECNs. Our broker-dealer subscribers can choose from the tailored trading models we offer through OTC Link ATS, OTC Link ECN, and OTC Link NQB to best suit their needs. Subscriber growth is also a testament to the value of our network, as broker-dealers use our regulated trading systems to serve investors and find better trade executions. Following the SEC's amendments to Rule 15c2-11 last year, OTC Link ATS' role as a qualified IDQS has allowed our subscribers to rely on our publicly available determinations regarding Rule 2-11 compliance.

Our work eases broker-dealer regulatory burdens, increases the number of securities available to trade, and supports a more transparent public market. Our critical regulatory role is now an integral role and part of the fabric of our nation's markets, a responsibility we take with the utmost dedication to serving our subscribers. Data-driven markets improve information for investors while supporting industry-wide compliance initiatives. We intend to build our enhanced regulatory role to create new opportunities for our clients to be more successful. Security and uptime of our core SCI-regulated trading systems are always a top priority. Throughout the first quarter of 2022, we delivered consistent, reliable service to our broker-dealer community. It is a testament to our engineering and operations team's focus on quality of service and system security.

Demand for our corporate services products and services remained strong in the first quarter, drawing on the momentum generated last year. The Rule 2-11 changes led to significant growth in demand for our disclosure and news services, and our OTCQX and OTCQB markets continued to expand. The nearly 1,800 companies on these markets as of the end of the first quarter exemplify the value of our data-driven premium market standards and technology platform for digitalizing disclosure, demonstrating compliance, and distributing governance credentials. Our market data licensing business also continued to grow during the first quarter. While the number of non-professional users declined, reflecting lower retail participation in the U.S. equity markets, as well as changes in our broker-dealers moving to enterprise licenses, the broader global and domestic interest in our markets and the data we provide led to strong increases in professional users and enterprise subscribers.

We are thrilled to have recently closed our acquisition of substantially all of the assets of Blue Sky Data Corp. We have long felt this acquisition was the right fit for our company and our subscribers. We now offer comprehensive data regarding state Blue Sky law compliance for over 100,000 equity and debt securities, in addition to the federal compliance data we already provide. Our Blue Sky data offering will help broker-dealers, financial advisors, public companies, investors, and other interactive market participants improve their understanding of, and compliance with state securities laws. It is a multi-sided platform business where increased compliance by issuers and improved automation by broker-dealers will benefit both sides. Our market data and technology teams are working hard to quickly integrate the Blue Sky Data Corp business and onboard Blue Sky subscribers that are new clients.

We are also excited to welcome several new employees as part of the transition to the OTC Markets team. With the addition of Blue Sky Data, we remain focused on growing our global subscriber base and provide enhanced compliance data to a wider group of industry participants. Throughout the first months of 2022, we have continued to pursue our four strategic initiatives structured around continuing to serve our clients and shareholders. One, drive sustainable revenue growth across each of our business lines that increases the long-term per-share earnings power. Two, commercialize our enhanced regulatory status under Rule 2-11 to create new opportunities for public companies and broker-dealers. Three, advocate for additional regulatory recognition of our markets to increase the value of being public. Four, pursue corporate development efforts to grow and diversify our product suite and client base.

In closing, I'm pleased to announce that on May 10th, our board of directors declared a quarterly dividend of $0.18 per share, payable later this month. This dividend reflects our ongoing commitment to providing superior shareholder returns. With that, I will turn the call over to Antonia.

Antonia Georgieva
CFO, OTC Markets Group

Thank you, Cromwell. Thank you everyone on the call today for joining us for the review of our first quarter results. As I discuss our results for the quarter ended March 31, 2022, any reference made to prior period comparatives will refer to the first quarter of 2021. I would like to start by recognizing the continued commitment of our entire OTC Markets team to supporting our subscribers and delivering on our strategic priorities. Turning to page 12 for an overview of our first quarter 2022 revenues. Coming off of a remarkable year of growth in 2021, OTC Markets Group continued to benefit from the strong customer demand for our corporate services products and market data licensing offerings while experiencing a significant moderation of trading activity and reduced retail participation in the U.S. equity markets.

We generated $25.9 million in gross revenues, flat as compared to the same prior period, while revenues less transaction-based expenses increased 8%. In our OTC Link business, gross revenues declined 47%, primarily as a result of lower trading volumes and consequently lower transaction-based revenues generated by OTC Link ECN. The surge in trading activity that we experienced in early 2021 to over 70,000 transactions per day, moderated over the course of the year and remained at more normalized levels in the first quarter of 2022 at approximately 39,000 transactions per day. As a result, in the first quarter, OTC Link ECN saw a 64% decline in gross revenues with an offsetting decline in transaction-based expenses of 57%.

The overall decline in OTC Link revenues was partially offset by growth in revenue from our Consolidated Audit Trail reporting service and our fixed connectivity services. OTC Link ECN continued to attract new subscribers and ended the first quarter with 98 subscribers, up from 82 subscribers as of March 31st, 2021. On OTC Link ATS, we saw a reversal of a long-term trend of broker-dealer consolidation and an increase in our subscribers to 90 subscribers , up from 82 subscribers at the end of the prior year period. Trading volumes are highly unpredictable and could decline further. Furthermore, changes in our broker-dealer subscribers' trading behavior could also impact the transaction-based revenues and transaction-based expenses that OTC Link generates. Revenues from our market data licensing business increased 9%, with revenues from professional users up 12%, driven by a 10% increase in pro user count.

With respect to non-professional users, we saw a reduced level of retail participation in the U.S. equity market, which drove a 31% decline in our non-pro user count and a corresponding 26% decrease in revenues from non-pro users. Historically, and in the normal course of business, we have seen significant fluctuations in the number of non-professional users, and we may experience a further decline in the coming months. Offsetting that was a strong 19% growth in revenues from internal system licenses, delayed data licenses, and other data services, and a 20% increase in broker-dealer enterprise license revenues. Turning to our corporate services business. Corporate services revenues grew by 51% in the first quarter, with strong growth in revenues from our premium OTCQX and OTCQB offerings, as well as our DNS product, which increased 26%, 52%, and 120% respectively.

As a result of the enhanced current information requirements under Rule 2-11, during 2021, a significant number of companies sought to join our OTCQX and OTCQB markets or to subscribe to our DNS product. The higher number of corporate services subscribers in turn drove the growth in revenues quarter over quarter. Contributing to the growth were also incremental price increases for our OTCQX and OTCQB market tiers that became effective January 1st, 2022. In the first quarter, we added 33 OTCQX companies compared to 52 new sales in the prior quarter. We ended the current quarter with 571 companies on the OTCQX market, up from 482 companies at the end of the prior year period.

On OTCQB, we added 113 new companies in the first quarter compared to 108 new companies added in the prior quarter, and finished with 1,224 OTCQB companies, up from 962 OTCQB companies at the end of the prior year period. We also saw a significant increase in Pink companies subscribing to DNS and other products to 1,584 at the end of the quarter, double the number at the end of the prior year period. Turning to page 13 for a review of our expenses. On a quarter-over-quarter basis, operating expenses increased by 12%. The primary driver was a 14% increase in compensation and benefits, reflecting higher headcount, annual salary increases, an increase in incentive compensation, and higher commissions.

IT infrastructure costs increased 20%, also contributing to the overall increase in operating expenses. Compensation and benefits comprised 68% of our total operating expenses during the first quarter, compared to 67% in the prior year period. In summary, on page 14, we delivered solid results during the first quarter of 2022, with income from operations increasing 3% and operating margin expanding to 34.4%, up from 33.2% in the prior year quarter. Net income increased 11%, while our diluted earnings per share grew 9%. In addition to certain GAAP and other measures, management utilizes adjusted EBITDA, which is a non-GAAP measure excluding non-cash stock-based compensation expenses. Our adjusted EBITDA was $10.3 million in the first quarter of 2022, up 4%, and our adjusted diluted earnings per share were $0.84, up 2%.

Cash flows from operating activities amounted to $0.5 million compared to $3.6 million in the prior quarter. The higher net income we generated in the first quarter of 2022 was more than offset by greater changes in assets and liabilities due to timing of payments to vendors and taxing authorities. Free cash flows for the quarter were $0.3 million compared to $3.4 million in the prior year quarter. Turning to page 15. During the first quarter of 2022, we returned a total of $4.9 million in the form of dividends and through our stock buyback program, an increase of 49% compared to $3.3 million in the prior year quarter.

We remain focused on our strategic initiatives on enhancing the value of our products and services to issuers and broker-dealer subscribers, on growing our business and delivering long-term value to our stockholders. With that, I would like to thank everyone for your time, and I'll pass it back to the operator to open the line for questions.

Operator

Thank you. As a reminder, to ask a question, you will need to press star one on your telephone. To withdraw your question, press the pound key. Please stand by while we compile the Q&A roster. Our first question comes from Chris McGinnis with Sidoti & Co. Please go ahead.

Chris McGinnis
Special Situation Equity Analyst, Sidoti & Company

Good morning. Thanks for taking my question. Nice quarter.

Cromwell Coulson
President and CEO, OTC Markets Group

Thank you.

Chris McGinnis
Special Situation Equity Analyst, Sidoti & Company

Good morning. Can you just discuss maybe your thoughts around kind of the rising interest rate environment and a possible slowdown in the global economy? Just, you know, how do you think about that impacting the business kinda going forward and, you know, what measures can you take in place to kinda maybe offset that?

Dan Zinn
General Counsel and Chief of Staff, OTC Markets Group

Yeah, Cromwell. Yeah, go ahead.

Cromwell Coulson
President and CEO, OTC Markets Group

Hey, Chris. Thanks for that question. I am not a highly skilled global economist and able to, you know, predict what is gonna take place in the future. Also, I have learned from my history as a trader, when you've actually timed something perfectly, you get stuck in that market, in that prediction, and you kind of get into a corner. The way we look at it is, you know, we wanna be in business on the sunny days, and we wanna sail safely through the stormy days. We have a mix of business lines. Some of them give us a little bit more predictability into what we're seeing.

You know, in the cycle that we've seen right now, we don't have the trading volume business, but we do have for transaction counts, but we are actually seeing a lot of data flowing through the system, so we have to keep improving the system. On the business side, we've strengthened, you know, really because of the 2-11 process, the ability for companies to want to be engaged in making sure that they're distributing current disclosure, they're demonstrating their compliance with securities law, and they're also, you know, demonstrating their ESG credentials. They're really their governance and their kind of global citizenship of complying with laws.

That side of it is, in that environment, we're seeing pretty strong retention in our corporate services and our market data business, and that could change. We will adjust the business as that goes forward. Now, we really believe we have an opportunity to build commercial value on top of what is the regulatory part of 2-11, and that's where we get the long-term expansion of the business. You know, there's more companies going public around the world on their local exchanges. That's a good opportunity. There's a real line blurring between public and private markets. That's an opportunity. None of these opportunities we have direct control over the immediate future. You know, so we play, we look at where our revenues are. We have a margin.

You know, that could tighten up if it gets worse, but we will always, you know, get our costs in line with if the environment gets worse because you know, we wanna be coming out of any storm strong.

Chris McGinnis
Special Situation Equity Analyst, Sidoti & Company

No, I appreciate that. Thanks for that answer. Just around the Blue Sky Data Corp acquisition, can you just talk about how quickly you expect that to be integrated? Could you add any profit metrics around that, or how do you expect to monetize that under your platform? Thank you.

Cromwell Coulson
President and CEO, OTC Markets Group

I'll give a high level on that. Just as we approach this acquisition, which was a bit tough on the team, the idea of cut it close was we wanted to integrate the acquisition into our platform, that it's our technology, that we're not running their legacy technology. They had a very high-quality reputation, but it's a handcrafted product. We wanted to change the process and use what we built for 2-11 and our own Blue Sky product, very quickly take their knowledge to compare our feed to their feed and expand the areas we didn't cover while adding in the areas they didn't cover. You know, our plan is to have everything cut over by the end of June. Which gives us some real room.

The second part is they have skilled people who both in the domain knowledge and client service as well as data quality specialists. It gives us revenues to support at a different point in the business process to improve our data quality. That's where we look at it from that side. I mean, I wish we could do numerous acquisitions like this. There's not that many out there. There's gonna be other acquisitions where we have to take on legacy technology that we have to run, and we can't consolidate it in. That's our, you know, it's. You know, Blue Sky Data is a great product that fits really well with us.

Antonia Georgieva
CFO, OTC Markets Group

Chris, to add, in terms of the impact or benefit for our business, we expect to add approximately 30 clients with the Blue Sky transaction. If you think of where it fits perfectly, we do have a Blue Sky product in our data market data licensing business, and this acquisition adds a lot of depth and breadth for that product in terms of the client opportunity. That's where we see the greatest financial benefit.

Chris McGinnis
Special Situation Equity Analyst, Sidoti & Company

Great. I appreciate that.

Cromwell Coulson
President and CEO, OTC Markets Group

One last point is how we look at acquisitions. You know, you can put whatever numbers you want in the spreadsheet and what their exit value of. The real part is can we be a good custodian and grow the revenues? You know, put in and create more demand, and then also find other products that can solve client problems. Our making big statements coming into the acquisition is, you know, I think we'd much prefer to have a track record three years later and say, "This is the revenues that we created, and this is the other problems we were able to solve that clients are willing to pay us for.

Chris McGinnis
Special Situation Equity Analyst, Sidoti & Company

Sure. No, I appreciate that. Maybe one just last question from me. You know, following c2-11, are you continuing to see more companies join post the quarter itself, you know, still under the c2-11 rule?

Antonia Georgieva
CFO, OTC Markets Group

Chris, I think the numbers speak for themselves. As you saw, we have seen an increased number across QX, QB, and the Pink subscribers that pay for DNS. As you would recall, in the past, our Pink subscribers or subscribers to DNS tend to have a little higher turnover than our premium markets. In any given quarter, we may see companies joining versus removing themselves from a paid subscriber due to compliance reasons or being acquired or for all sorts of other reasons. Yes, we do continue to see strong demand for our products across corporate services in 2022.

Dan Zinn
General Counsel and Chief of Staff, OTC Markets Group

Chris, just to add from the 2-11 perspective, you know, that it's sort of what we talked about a little bit last year, where there was this event, a point-in-time event, where a number of companies were pointing to that compliance date as a real driver for joining particularly our DNS service and making sure they could get their disclosure out to investors. We've seen that number stay relatively steady, as you can see from the quarterly report and the earnings. That was kind of what we were hoping and expecting would happen at that point.

The additional companies coming on to QX and QB, you know, we've attributed over time some of that to the 2-11 impact and the additional attention on our markets, as well as just our strong outbound sales effort. That has all remained consistent. It's kind of a mix of 2-11 and just the general environment and sales effort that's led to the results.

Chris McGinnis
Special Situation Equity Analyst, Sidoti & Company

Sure. No, I appreciate that. Thank you very much for the time, and I'll jump back in queue.

Dan Zinn
General Counsel and Chief of Staff, OTC Markets Group

Thanks, Chris.

Operator

Thank you. As a reminder, if you have a question, please press the star then one key. Seeing none.

Dan Zinn
General Counsel and Chief of Staff, OTC Markets Group

Operator-

Operator

No questions from the queue at this time. I would like to turn the call back over to management for any closing remarks. Actually, we do have a follow-up from Chris McGinnis. Please go ahead.

Chris McGinnis
Special Situation Equity Analyst, Sidoti & Company

Yeah, thanks. Sorry about that. I didn't realize. I guess just on the cost, Antonia, just maybe on the cost for 1Q, that compensation level. That starts to trend down a little bit, just kinda given, you know, I think some resets in Q1. You know, can you just talk about the cost structure as you expect throughout the year?

Antonia Georgieva
CFO, OTC Markets Group

Yes. You did see an increase of our operating expenses of 12%, quarter-over-quarter, driven mostly by our compensation and benefits expense. There were some discrete reasons for that. As we continue to invest in our highly talented team, we focus very much on remaining competitive, and we did implement certain annual salary increases at the end of 2021, which became effective at the beginning of the year. That contributed to approximately 1/3 of the overall increase in our comp and benefits, with the rest due to our higher headcount. We will, as Cromwell pointed out, add a handful of employees from Blue Sky Data Corp. So you should expect that to impact our compensation and benefits line item starting from June and onwards. We remain focused on maintaining the security, reliability, and availability of our systems.

In terms of ongoing investment in IT and infrastructure, we would see that continuing as well as it has in the past. That was a 20% increase vis-à-vis last quarter and contributed to the overall growth in expenses. Those are the two main items I would focus on, Chris, going forward. The remaining, we tend to run pretty lean for the remaining line items, and we tend to be quite thoughtful in terms of our cost control. There are a few other variable elements there that we have discussed in the past within professional and consulting. We have variable expenses related to the trading volumes. Those would move around pretty much in lockstep with the ECN revenue and Link's revenue. We saw a bit of a decline in that line item considering the lower volumes this quarter.

Overall, the rest of the expense structure remains relatively fixed, and we have more control over some of these discretionary expenses. We will remain very focused, to Cromwell's earlier point, on our margin, on our cost structure. How exactly it will evolve quarter-over-quarter, we will obviously communicate at the right time. Those are the main items I point out in terms of things to watch for.

Chris McGinnis
Special Situation Equity Analyst, Sidoti & Company

Great. Well, very helpful. Thanks, Antonia. Just a kind of a question, thinking about, you know, the changes within market data around the professional user, non-professional user. Is one of those two more profitable than the others, you know, just kinda given that drop off in the non-professional user?

Antonia Georgieva
CFO, OTC Markets Group

Our pricing is available on our website. As you know, we are open, transparent, and connected, and we do publish our pricing schedules for all product lines. You can see that certainly the professional users have a higher pricing rates than the non-professional users, and that indeed would imply a greater impact on our revenue, market data licensing revenue in terms of changing user counts.

Chris McGinnis
Special Situation Equity Analyst, Sidoti & Company

Okay, great. No, thank you for that. Just lastly, you spent a lot of time on your analyst day around, you know, the international markets. If you could just talk a little bit about the investment to kinda go out and grab those, you know, those companies that are out there in those newer markets that you're targeting. Thank you.

Cromwell Coulson
President and CEO, OTC Markets Group

Yeah. Chris, I think it's. You know, the way we think about growing revenues is, you know, there's. We've been a company that's building a platform. So for a good part of it, we've been working on new things to sell. There's really, you know, I look at it, there's kinda three parts of potential revenues. There's one part of potential revenues, which we saw under Rule 2-11 was. We have a product. It's understood what it's used for and it's needed for, and people are coming in, and you just have to sell it. The more you sell, the power of the platform, you know, scales and the network effect takes place.

That's a really important point, but it's understood we have the product, and it's understood by the subscriber to that product of what it does and the real value for them. There's the second part is where we have the platform, but the value and understanding of the potential paying client is not where it needs to be yet. I would say in Canada, our international markets are clearly understood. The value proposition is, you know, well-defined, and the time to market and usefulness is there from the client perspective. That's a product that we just wanna sell, sell. There are certain industries where that takes place because we have a critical mass in that industry and we're able to jump to different countries.

In the global space, there's a second side is really where you've got the capacity, you've built the platform, but you really need to build up the client understanding. That's our global expansion. You know, that's in so many ways of our domestic expansion. You know, how could you do an institutional registered offering onto our OTCQX market as we had a cannabis REIT, a U.S.-based cannabis REIT due in last fall, and getting that understanding out there, the value and how that works smoothly is. Then there's the third category is the stuff where we're building something new. You know, there, we haven't fully built a functioning piece that we've seen people using, but we're also, you know, there's not an understanding fully how to use these things.

You know, there's a lot of companies always out there in the space with ideas for that, and really their client is the venture capitalist community rather than the paying clients often. We work on those things too, but it's really a balance of selling, you know, the known product, educating to make the unknown known, and building the next thing is how I see the opportunity. You can add up the numbers of all the global companies around the world. You can also add up how many companies are on our premium markets versus how many total securities are traded on our market. You know, we will keep investing in our platform.

You know, we look at our margin as a way to be good commercial operators, have safety to stay profitable through tough times. We also look at revenues that we're gonna keep reinvesting in the products that clients are paying for, so they get a stronger platform, that's constantly improving.

Chris McGinnis
Special Situation Equity Analyst, Sidoti & Company

Great. Well, I appreciate the time today again. Thanks for taking my questions, and good luck in Q2.

Cromwell Coulson
President and CEO, OTC Markets Group

Thank you, Chris.

Dan Zinn
General Counsel and Chief of Staff, OTC Markets Group

Thanks, Chris.

Operator

Speakers, I'm showing no further questions at this time. I'll turn the call back over to management for any closing remarks.

Dan Zinn
General Counsel and Chief of Staff, OTC Markets Group

Thanks, operator. Maybe before Cromwell gets to his closing remarks, we had a question come in through a different channel that I just wanted to pose to Cromwell. I think, Cromwell, you've done a nice job of answering this throughout your answers to some of Chris's questions. The question was, I know you did not give guidance, nor do you pre-commit to revenue targets, but I was hoping you could give investors an idea of how you think internally about the revenue opportunity you're going after over the long term, say, the 5- 10 year period. Cromwell, anything you wanna add on that?

Cromwell Coulson
President and CEO, OTC Markets Group

Yep. Thanks, Dan, and thank you to the person who sent in that question. You know, for the long term, we have immediate products that we think we can sell more of, and that's very helpful because that lets us provide returns on our investment of building and supporting those products back to our shareholders but also keep investing in the future. You know, we will continue to invest in our people and platform forever. Those opportunities are we have immediate opportunities in front of us, which you can see which of our products have been growing. We have other opportunities where you can see we're marketing out to clients to talk about, and we're trying to create more educational material.

Then there's other opportunities where they're still in the figuring out stage, and we, you know, don't really talk a ton about those, with the exception of trying to find first mover clients and understand that area. You know, what I would say is, you know, I'm still excited. I'm a large shareholder of the company, and I think there are a lot of things that we can do, especially in a place where the large global exchange groups have a different problem set.

They're also seeking twice the margins we want and twice the margins that we think are well earned to support the broker-dealer community, to support companies and that value of what we're doing and our focus of building a market that can fit a wide spectrum of different companies, securities, broker-dealers and appropriately price risk and deliver best execution is a real opportunity.

Dan Zinn
General Counsel and Chief of Staff, OTC Markets Group

All right. That's great. Thanks, Cromwell. I'll turn it back to you for any remaining closing remarks.

Cromwell Coulson
President and CEO, OTC Markets Group

Thank you, operator. I want to thank each of you for joining us today. I would encourage you to read our first full quarter report and the accompanying earnings press release. Links to both are available on the investor relations page of our website. On behalf of the entire team at OTC Markets Group, we wish you and your families continued health and safety, and we look forward to updating you on key initiatives that continue to shape the integrity and the competitiveness of the public markets.

Operator

Ladies and gentlemen, this concludes today's conference call. Thank you for your participation. You may now disconnect.

Powered by